STCOSD
NKTR icon

Sageworth Trust Company of South Dakota’s Nektar Therapeutics NKTR Stock Holding History

Sageworth Trust Company of South Dakota’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed – – 499
2022
Q2 		$0 Hold
6
– – ﹤0.01% 643
2022
Q1 		$0 Sell
6
-25
-81% -$3.7K ﹤0.01% 658
2021
Q4 		$6K Buy
+31
New +$6.72K 0.01% 493

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Sageworth Trust Company of South Dakota's NKTR Position: Q3 2022 in Review

Sageworth Trust Company of South Dakota sold out of Nektar Therapeutics (NKTR) in Q3 2022, closing a stake of 6 shares.

Sageworth Trust Company of South Dakota first reported a position in NKTR in Q4 2021 and held it in 3 quarters. The position peaked at $6K in Q4 2021. 231 funds tracked by Wall St. Rank hold NKTR as of Q3 2022.

  • Sageworth Trust Company of South Dakota reported no remaining Nektar Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Sageworth Trust Company of South Dakota sold 6 Nektar Therapeutics shares in Q3 2022.
  • Sageworth Trust Company of South Dakota first reported a position in Nektar Therapeutics in Q4 2021 and held it in 3 quarters.
  • Sageworth Trust Company of South Dakota's Nektar Therapeutics position peaked at $6K in Q4 2021.
  • 231 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2022.

Based on Sageworth Trust Company of South Dakota's 13F filing for Q3 2022, filed 2 Nov 2022.